Evidence map›Paper›PMID 35681790›Full record

ArticleCancers2022

Multiparametric Phenotyping of Circulating Tumor Cells for Analysis of Therapeutic Targets, Oncogenic Signaling Pathways and DNA Repair Markers.

Stephanie Staudte, Konrad Klinghammer, Philipp Sebastian Jurmeister, Paul Jank, Jens-Uwe Blohmer, Sandra Liebs, Peter Rhein, Anja E Hauser, Ingeborg Tinhofer

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Stephanie StaudteDepartment of Radiooncology and Radiotherapy, Charité University Hospital, 10117 Berlin, Germany.
Konrad KlinghammerDepartment of Hematology and Oncology, Charité University Hospital, 10117 Berlin, Germany.ORCID 0000-0001-6425-4833
Philipp Sebastian JurmeisterInstitute of Pathology, Charité University Hospital, 10117 Berlin, Germany.
Paul JankInstitute of Pathology, Philipps-University Marburg and University-Hospital Marburg (UKGM), 35039 Marburg, Germany.ORCID 0000-0001-7076-0476
Jens-Uwe BlohmerBreast Cancer Center, Charité University Hospital, 10117 Berlin, Germany.ORCID 0000-0002-7969-250X
Sandra LiebsCharité Comprehensive Cancer Center (CCCC), Charité University Hospital, 10117 Berlin, Germany.ORCID 0000-0002-7099-0340
Peter RheinLuminex B.V., A DiaSorin Company, 5215 MV's-Hertogenbosch, The Netherlands.
Anja E HauserDepartment of Rheumatology and Clinical Immunology, Charité University Hospital, 10117 Berlin, Germany.ORCID 0000-0002-7725-9526
Ingeborg TinhoferDepartment of Radiooncology and Radiotherapy, Charité University Hospital, 10117 Berlin, Germany.
Charité - Universitätsmedizin Berlin · DEGerman Cancer Research Center · DELeibniz Association · DEPhilipps University of Marburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Detection of circulating tumor cells (CTCs) has been established as an independent prognostic marker in solid cancer. Multiparametric phenotyping of CTCs could expand the area of application for this liquid biomarker. We evaluated the Amnis

Indexed as

Amnis®breast cancercirculating tumor cellshead and neck squamous cell carcinomaimaging flow cytometryliquid biopsymultiparametric phenotyping

Identifiers

PMID35681790
PMCPMC9179910
OpenAlexW4281681565

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.